A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin

Hepatocellular Carcinoma Resectable Clinical Trial

Official title:
An Efficacy and Safety Study of Camrelizumab in Combination With Apatinib Mesylate and Oxaliplatin for Neoadjuvant Therapy in Patients With Potentially Resectable Hepatocellular Carcinoma.

Status Not yet recruiting

Clinical Trial Summary

This is a prospective, single-arm, single-center, clinical research.This trial will explore the efficacy and safety of Camrelizumab in combination with Apatinib Mesylate and Oxaliplatin for neoadjuvant therapy in patients with potentially resectable hepatocellular carcinoma.

Clinical Trial Description

There is no high-level evidence on the efficacy of systemic therapy in neoadjuvant studies for hepatocellular carcinoma, and guidelines recommend TACE as the treatment of choice. Given that combination therapies such as immunotherapy in combination with targeted therapy and immunotherapy in combination with chemotherapy have achieved good efficacy in systemic therapy for liver cancer, this study is intended to explore the efficacy of TACE. In this study, we propose to explore the use of kareliozumab in combination with apatinib and oxaliplatin for the treatment of hepatocellular carcinoma. In this study, we propose to investigate the efficacy and safety of neoadjuvant therapy with kalilizumab in combination with apatinib and oxaliplatin in patients with potentially resectable hepatocellular liver cancer. ;

Study Design

Related Conditions & MeSH terms

Carcinoma
Carcinoma, Hepatocellular
Hepatocellular Carcinoma Resectable

Clinical Trial Details

NCT number	NCT04850040
Study type	Interventional
Source	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact	Jianping Xu, Master's Degree
Phone	13651379626
Email	13651379626@139.com
Status	Not yet recruiting
Phase	Phase 2
Start date	May 6, 2021
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06157060` - Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
Not yet recruiting	`NCT06449846` - Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
Completed	`NCT06294808` - Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCC
Recruiting	`NCT06003673` - A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC	Phase 4
Recruiting	`NCT05766605` - Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial	Phase 3
Completed	`NCT04177316` - Hypermethylation of VTRNA2-1 Promoter in HCC Outcome